Breakpoints
The SIDP Podcast

The New Scoop on Poop: Updates in the Management of C. difficile infections

Dr. Kevin Garey (@GareyKgarey), Dr. Kelly Reveles (@KellyReveles), Dr. Mandelin Cooper, and host Dr. Rachel Britt (@RachelBPharmD) discuss proposed updates of the IDSA-SHEA C. difficile guidelines, including: fidaxomicin over oral vancomycin as first-line therapy, the roles and logistical hurdles of fecal microbiota transplant, bezlotoxumab, and the pros and cons of prophylaxis.

Timestamps

1:16 - Panel introductions 3:19 - Fidaxomicin vs PO vancomycin for first occurrence 7:21 - Fidaxomicin cost effectiveness 11:26 - Factors to consider for health systems when considering switch to fidaxomicin 14:23 - Fidaxomicin vs PO vancomycin for recurrences 17:52 - Role of pulsed and tapered PO vancomycin 19:57 - Role of fecal microbiota transplant (FMT) 22:24 - Challenges of FMT and where pharmacy fits in 27:27 - Bezlotoxumab 31:54 - Feasibility issues with bezlotoxumab and strategies to address them 35:25 - CDI prophylaxis 40:28 - Stewardship's role in reducing C. difficile infections

References

Fidaxomicin Cost-effectiveness

  • Reveles KR, et al. Pharmacotherapy. 2017;37(12):1489-97.
  • Watt M, et al. Infection. 2016;44(5):599-606.
  • Cornely OA, et al. J Antimicrob Chemother. 2018;73(9):2529-39.
  • Rubio-Terres C, et al. Eur J Clin Microbiol Infect Dis. 2019;38(6):1105-11.

Bezlotoxumab

  • Wilcox MH, et al. N Engl J Med. 2017;376:305-17.
  • Oksi J, et al. Eur J Clin Microbiol Infect Dis. 2019;38(10):1947-52.
  • Hengel RL, et al. Open Forum Infect Dis. 2020;7(4):ofaa097.

Bezlotoxumab Cost-effectiveness

  • Salavert M, et al. Adv Ther. 2018;35(11):1920-34.
  • Prabhu VS, et al. Clin Infect Dis. 2018;66(3):355-62.

Primary prophylaxis 

  • Pereiras MA, et al. Biol Blood Marrow Transplant. 2017; 23:S395. 
  • Ganetsky A, et al. Clin Infect Dis. 2019;68(12):2003-2009.
  • Mullane KM, et al. Clin Infect Dis. 2019; 68(2):196–203.

Secondary prophylaxis  

  • Carignan A, et al. Am J Gastroenterol. 2016;111:1834-1840.
  • Van Hise NW, et al. Clin Infect Dis. 2016;63:651-653.
  • Splinter et al. Ann Pharmacother. 2018;52:113-119.
  • Knight EM, et al. J Pharm Pract. 2019;:897190019825994.
  • Morrisette T, et al. Biol Blood Marrow Transplant. 2019;25(10):2091-2097.

A Lung Time Coming: Controversies in Community Acquired Pneumonia

Join Dr. Elizabeth Covington (@ewood_1875), Dr. Brandon Dionne (@BWDionne), Dr. Jason Pogue (@jpogue1), and Dr. David Ha (@DHpharmd) as they discuss new and old antibiotic therapies for community acquired pneumonia, just how typical are atypicals, what happened to HCAP, and much more! This episode was sponsored by an unrestricted educational grant from Paratek Pharmaceuticals

Time stamps: 00:00 Intro, guest bios 03:54 Procalcitonin 10:06 Pneumococcal and legionella antigen testing 16:30 Outpatient CAP therapy 23:40 Newer agents 31:18 Inpatient CAP therapy 39:09 Atypical coverage for admitted patients 44:27 Beta-lactam combination therapy 46:58 Ceftaroline vs ceftriaxone for pneumococcal pneumonia 55:23 Steroid use in CAP

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

Unsolicited Advice: An Honest Discussion of Burnout in Stewardship

Join Dr. Julie Szymczak @julieszymczak, Dr. Emily Heil @emilylheil, Dr. Zahra Kassamali Escobar @zkepharmd, and Dr. Erin McCreary @erinmccreary, for a discussion on stewardship burnout—what is it, who is at risk for it, and what can we do about it?

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

“Mind the Gap”: Antimicrobial Stewardship at Transitions of Care

Antimicrobial stewardship is often an inpatient effort and overlooked at transitions of care. Dr. April Dyer (@aprildyerid) and Dr. Rachel Kenney (@rkenneypharmd) share insight with host Dr. David Ha (@DHpharmD) on current practice and barriers, and strategies for pharmacists to bring antimicrobial stewardship in the discharge process. 

Episode content:

  • 00:14: Welcome and introductions:
  • 04:39: Project overview: "Developing Patient Safety Outcome Measures and Measurement Tools for Antimicrobial Stewardship Program”
  • 06:45: Scope of the problem (Scarpato et al.)
  • 07:56: Michigan data (Vaughn et al.)
  • 09:13: Building a business case
  • 12:32: Where to Start?
  • 12:54: Henry Ford Health System experience
  • 15:18: IT solutions
  • 17:22: 1% rule
  • 20:26: Identifying and engaging key players
  • 20:47: Outpatient pharmacy
  • 22:29: Skilled nursing facilities
  • 23:19: Case management relationship
  • 24:23: Barriers to implementation
  • 29:08: Quantifying total duration 
  • 30:00: Identify electronic methods to capture total duration therapy attributable to hospitalization
  • 32:16: CDC recommendation "Use the shortest effective antibiotic duration" 
  • 33:16: Final remarks & acknowledgements
  • 34:38: Outro

References:

  1. Scarpato SJ, Timko DR, Cluzet VC, et al. An Evaluation of Antibiotic Prescribing Practices Upon Hospital Discharge. Infection Control and Hospital Epidemiology. 2017;38(3):353-355. doi:10.1017/ice.2016.276
  2. Madaras-Kelly KJ, Burk M, Caplinger C, et al. Total duration of antimicrobial therapy in veterans hospitalized with uncomplicated pneumonia: Results of a national medication utilization evaluation. Journal of Hospital Medicine. 2016;11(12):832-839. doi:10.1002/jhm.2648
  3. Feller J, Lund BC, Perencevich EN, et al. Post-discharge oral antimicrobial use among hospitalized patients across an integrated national healthcare network. Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases. 2020;26(3):327-332. doi:10.1016/j.cmi.2019.09.016
  4. Daniels LM, Weber DJ. Interventions to improve antibiotic prescribing at hospital discharge: A systematic review. Infection Control and Hospital Epidemiology. Published online September 1, 2020:1-4. doi:10.1017/ice.2020.367
  5. Vaughn VM, Gandhi TN, Chopra V, et al. Antibiotic Overuse after Hospital Discharge: A Multi-Hospital Cohort Study. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. Published online September 11, 2020. doi:10.1093/cid/ciaa1372
  6. Dyer AP, Dodds Ashley E, Anderson DJ, et al. Total duration of antimicrobial therapy resulting from inpatient hospitalization. Infection Control and Hospital Epidemiology. 2019;40(8):847-854. doi:10.1017/ice.2019.118
  7. Bianchini ML, Kenney RM, Lentz R, Zervos M, Malhotra M, Davis SL. Discharge Delays and Costs Associated with Outpatient Parenteral Antimicrobial Therapy for High priced Antibiotics. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. Published online October 31, 2019. doi:10.1093/cid/ciz1076

Disclosures Dr. April Dyer and Rachel Kenney report no relevant financial disclosures. SIDP reports no relevant financial disclosures. 

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

Is More Better? The Role of Combination Therapy for MRSA

Host Erin McCreary (@erinmccreary) and expert panelists Dr. Katie Barber (@IDKatieBarb), Dr. Warren Rose (@Warren_E_Rose), and Dr. Steven Tong (@syctong) discuss data from early laboratory work to randomized, clinical trials for various antibiotic combinations used in the treatment of MRSA bacteremia. This was our most requested topic to cover on Breakpoints, and we hope you enjoy!

Please complete this brief survey to help us continue to improve Breakpoints content: https://docs.google.com/forms/d/e/1FAIpQLSeriW-TAgiBik2_gdJllCZ4WqADhUyFIZtTAgYAYxRU5YU3hA/viewform?vc=0&c=0&w=1&flr=0

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

What You May Have Missed Due to COVID-19: ID Literature Updates 2020 Part 2

Erin McCreary (@erinmccreary) and Ryan Shields (@ryankshields) discuss notable infectious diseases publications from the first half of 2020.

Papers discussed:

1) Van Duin D, et al. Lancet Infect Dis. 2020 Jun;20(6):731-741. doi: 10.1016/S1473-3099(19)30755-8. 2) Livermore DM, et al. Clin Infect Dis. 2020 Feb 6;ciaa122. doi: 10.1093/cid/ciaa122. 3) Falcone M, et al. Clin Infect Dis. 2020 May 19;ciaa586. doi: 10.1093/cid/ciaa586. 4) Lodise TP, et al. J Antimicrob Chemother. 2020 May 28;dkaa197. doi: 10.1093/jac/dkaa197. 5) O’Donnell JN, et al. Clin Ther. 2020 Jul 16;S0149-2918(20)30315-5. doi: 10.1016/j.clinthera.2020.06.005. 6) Abdul-Aziz MH, et al. Intensive Care Med. 2020 Jun;46(6):1127-1153. doi: 10.1007/s00134-020-06050-1. 7) Cusumano JA, et al. Am J Health Syst Pharm. 2020 Jul 7;77(14):1104-1112. doi: 10.1093/ajhp/zxaa128. 8) Roberts JA, et al. Clin Infect Dis. 2020 Mar 9;ciaa224. doi: 10.1093/cid/ciaa224. 9) Ackerman A, et al. Antimicrob Agents Chemother. 2020 May 21;64(6):e00066-20. doi: 10.1128/AAC.00066-20. 10) Tong SYC, et al. JAMA. 2020 Feb 11;323(6):527-537. doi: 10.1001/jama.2020.0103. 11) Jones BE, et al. JAMA Intern Med. 2020 Feb 17;180(4):552-560. doi: 10.1001/jamainternmed.2019.7495. 12) Cheng MP, et al. Clin Infect Dis. 2020 Jul 15;ciaa1000. doi: 10.1093/cid/ciaa1000.

For BCIDP credit, visit https://sidp.org/BCIDP

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

What You May Have Missed Due to COVID-19: ID Literature Updates 2020 Part 1

Erin McCreary (@erinmccreary) and Ryan Shields (@ryankshields) discuss notable infectious diseases publications from the first half of 2020!

Papers discussed:

1) Rybak MJ, et al. Am J Health Syst Pharm. 2020 May 19;77(11):835-864. doi: 10.1093/ajhp/zxaa036. 2) Scheetz MH. Am J Health Syst Pharm. 2020 May 19;77(11):810-811. doi: 10.1093/ajhp/zxaa076. 3) Alosaimy S, et al. Clin Infect Dis. 2020 July 27;ciaa1039. doi: 10.1093/cid/ciaa1039. 4) Rhee C, et al. Clin Infect Dis. 2020 May 6;ciaa059. doi: 10.1093/cid/ciaa059. 5) Heil EL, et al. Pharmacotherapy. 2020 Apr;40(4):368-371. doi: 10.1002/phar.2384. 6) Townsend SR, et al. Clin Infect Dis. 2020 May 6;ciaa458. doi: 10.1093/cid/ciaa458. 7) Satlin MJ, et al. Clin Infect Dis. 2020 Feb 13;ciaa121. doi: 10.1093/cid/ciaa121. 8) Pogue JM, et al. Antimicrob Agents Chemother. 2020 Jan 27;64(2):e01495-19. doi: 10.1128/AAC.01495-19. 9) Ambrose PG, et al. Open Forum Infect Dis. 2020 Mar 13;7(7):ofaa084. doi: 10.1093/ofid/ofaa084. 10) Singh N, et al. JAMA. 2020 Apr 14;323(14):1378-1387. doi: 10.1001/jama.2020.3138. 11) van Delden C, et al. Clin Infect Dis. 2020 Jan 9;ciz1113. doi: 10.1093/cid/ciz1113. 12) Niederman MS, et al. Lancet Infect Dis. 2020 Mar;20(3):330-340. doi: 10.1016/S1473-3099(19)30574-2. 13) von Dach E, et al. JAMA. 2020 Jun 2;323(21):2160-2169. doi: 10.1001/jama.2020.6348. 14) Mergenhagen KA, et al. Antimicrob Agents Chemother. 2020 Feb 21;64(3):e02167-19. doi: 10.1128/AAC.02167-19.

For BCIDP credit, visit https://sidp.org/BCIDP

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

Expert Updates in Gram Negative Resistance: Q&A Session

This is part 2 of a continuing education series produced in partnership with the SIDP Education Center (SIDPEC) on gram-negative bacterial resistance. It features expert speakers, Drs. Keith Kaye (@Keith_S_Kaye) and Kimberly Claeys (@ClaeysKcclaeys) and host Julie Ann Justo (@julie_justo). If you missed part 1 of this series, delivered as a webinar lecture, please go to sidp.org/SIDPEC to view that portion of the series first. In this podcast, our experts answer a collation of > 150 questions from interested viewers on the nuances of gram-negative bacterial resistance, from real-world formulary considerations to microbiology lab implementation and more.

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

OPAT - The Final Frontier, Part 2

Gain insight into Outpatient Parenteral Antibiotic Therapy (OPAT) practices across the country from Drs. Jessie Ortwine (@jkortwine), Monica Mahoney (@mmpharmd), Keenan Ryan (@keenanconazole), Monica Donnelley (@DonnelleyMonica), and Meera Mehta.

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

Remdesivir: Ethical and Practical Considerations for Allocation, Tracking, and More

Drs. Julie Ann Justo (@julie_justo), Erin McCreary (@erinmccreary), and Helen Newland (@helennewland) discuss ethical allocation of Emergency Use Authorization remdesivir for patients with COVID-19.

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/